Norway· NO-ID_215BC545-87C6-438C-813C-8576D3AC5F78
Inrebic
A fedratinib product containing fedratinib, registered in Norway by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Fedratinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EJ02 (fedratinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Fedratinib · ATC L01EJ02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Fedratinib
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Norway (NO)
- ATC code
- L01EJ02
- ATC class
- Fedratinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_215BC545-87C6-438C-813C-8576D3AC5F78
- no_varenummer416887120NOK 61926.1
- gtin7640133688534
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
554 interactions on record for fedratinib.
Graded by severity as the source publishes them — 161 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fedratinib · interactions on record
554 records
- 161 severe
- 370 moderate
- 23 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fedratinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesInrebicCelgene Corporation
- CanadaINREBICBRISTOL-MYERS SQUIBB CANADA
- CzechiaINREBICBristol-Myers Squibb Pharma EEIG, Dublin
- SpainINREBIC 100 mg CAPSULAS DURASBristol-Myers Squibb Pharma Eeig
- FinlandInrebicBristol-Myers Squibb Pharma EEIG
- FranceINREBIC 100 mg, géluleBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- BelgiumInrebic 100 mgBristol-Myers Squibb Pharma
- IcelandInrebicBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Inrebic
- Liechtenstein · Inrebic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3dcf7cd3-9a28-4add-b499-cc2a23788746 GET /v1/drugs/3dcf7cd3-9a28-4add-b499-cc2a23788746?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsel, hard",
"source": "fest",
"status": "A",
"atc_name": "Fedratinib",
"merkevare_id": "ID_215BC545-87C6-438C-813C-8576D3AC5F78",
"name_form_strength": "Inrebic kaps 100 mg",
"prescription_group": "C"
}See everything about fedratinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.